Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.49 USD | +1.11% | +3.24% | -7.51% |
Financials (USD)
Sales 2024 * | 607M | Sales 2025 * | 620M | Capitalization | 1.93B |
---|---|---|---|---|---|
Net income 2024 * | -470M | Net income 2025 * | -386M | EV / Sales 2024 * | 2.43 x |
Net cash position 2024 * | 456M | Net cash position 2025 * | 310M | EV / Sales 2025 * | 2.62 x |
P/E ratio 2024 * |
-4.11
x | P/E ratio 2025 * |
-4.93
x | Employees | 1,022 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.22% |
Latest transcript on PTC Therapeutics, Inc.
1 day | +1.11% | ||
1 week | +3.24% | ||
Current month | -12.38% | ||
1 month | -11.68% | ||
3 months | -4.39% | ||
6 months | +9.49% | ||
Current year | -7.51% |
Managers | Title | Age | Since |
---|---|---|---|
Matthew Klein
CEO | Chief Executive Officer | 52 | 19-09-30 |
Pierre Gravier
DFI | Director of Finance/CFO | 39 | 23-07-12 |
Ellen Welch
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Glenn Steele
BRD | Director/Board Member | 79 | 15-06-14 |
Chairman | 72 | 01-07-31 | |
David Southwell
BRD | Director/Board Member | 63 | 05-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.35% | 16 M€ | -7.62% | ||
0.36% | 0 M€ | 0.00% | - | |
0.25% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 25.49 | +1.11% | 900 317 |
24-04-24 | 25.21 | -0.79% | 560,814 |
24-04-23 | 25.41 | -2.16% | 754,373 |
24-04-22 | 25.97 | +2.57% | 647,499 |
24-04-19 | 25.32 | +2.55% | 3,931,888 |
Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.51% | 1.93B | |
-2.26% | 104B | |
+1.41% | 97.42B | |
+0.79% | 22.2B | |
-17.84% | 21.23B | |
-11.11% | 18.33B | |
-42.83% | 16.35B | |
-17.63% | 15.06B | |
+4.55% | 13.98B | |
+32.11% | 11.66B |
- Stock Market
- Equities
- PTCT Stock